The Beijing genotype is found frequently in Asia ([@R1]--[@R3]) but also in outbreaks of multidrug-resistant tuberculosis (MDRTB) in various parts of the world, including Cuba, Germany, Russia, and Estonia ([@R4]--[@R7]). The largest known epidemic of MDRTB in North America was caused by the W strain, a variant of the Beijing genotype ([@R8],[@R9]). A recent study showed this strain's emergence and association with drug resistance in Vietnam ([@R10]). The Beijing genotype was also responsible for a recent outbreak of tuberculosis (TB) on the Canary Islands ([@R11]).

The relatively high degree of genetic conservation of Beijing genotype strains found in a widespread area ([@R12]) suggests a recent dissemination and, hence, selective advantages associated with this genotype of *Mycobacterium tuberculosis*. Recently, Beijing genotype bacteria were reported to carry mutations in putative mutator genes, which may explain a higher adaptability of these bacteria under stress conditions such as exposure to the intracellular environment or anti-TB drugs ([@R13]). These mutations may also be the basis of differential interaction between Beijing genotype bacteria and the host immune defense system suggested in a recent study in Indonesia ([@R14]).

In the Netherlands, MDRTB is affecting \<1% of new TB patients, in particular immigrants ([@R15]--[@R17]). The incidence of the Beijing genotype has not yet been described. The goal of our study was to determine whether the Beijing genotype is emerging in the Netherlands and whether this genotype is associated with multidrug resistance.

The Study
=========

Patient data were obtained from the Netherlands Tuberculosis Register, which is maintained by the Royal Netherlands Tuberculosis Association and has been in place since 1993. Municipal health services, which are responsible for the followup of all TB patients, send information using standardized, precoded forms on all reported TB cases to the register. The register includes information on demographic characteristics, case detection, risk groups, type of disease, treatment, and treatment outcome.

Isolates obtained from all 8,210 culture-positive patients underwent restriction fragment length polymorphism (RFLP)--typing with IS*6110* as a probe at the National Institute of Public Health and the Environment. The Beijing genotype was defined on the basis of spoligotype (no spacers 1--34; at least 4 of spacers 35--43) and a specific region A insertion ([@R18]). Certain IS*6110* RFLP-genotype families (clades 47 and 61) were consistently found to be Beijing genotype ([@R18]). Isolates were assigned to the Beijing genotype on the basis of the IS*6110* RFLP pattern ([@R18]). If any doubt about clade membership existed, we used spoligotyping for the final allocation.

The RFLP results for the period 1993--2000 were matched to patient data on the basis of date of birth, postal area code, and sex, resulting in a perfect match for 5,994 (73%) patients and a near-perfect match for 835 (10%) patients; overall, 83% of the samples matched (6,829 patients). During this period, the Beijing genotype was observed in 516 cultures, representing 6% of the 8,210 patients. In the matched dataset, 415 (6%) of 6,829 were of the Beijing genotype. The number of TB cases attributable to the Beijing genotype tended to increase over time (Figure; p\>0.05). This tendency was observed both among Dutch patients (r=0.66, 95% confidence interval \[CI\] --0.08 to 0.93) and non-Dutch patients (r=0.59, 95% CI --0.20 to 0.91) ([Figure](#F1){ref-type="fig"}). While the increase in the number of cases among immigrants may be associated with an overall increase of immigrants to the Netherlands during the study period, the increasing numbers among Dutch patients likely reflect an increasing incidence rate.
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The proportion of TB patients who had the Beijing genotype was significantly associated in univariate analysis with a later year of diagnosis, young age, nationality (increased among immigrants from Asia and decreased among those from Morocco, Turkey, Somalia, and other African countries, compared with Dutch citizens), and multidrug resistance ([Table](#T1){ref-type="table"}). These associations persisted in multivariate analysis ([Table](#T1){ref-type="table"}).

###### Risk factors for the Beijing genotype of *Mycobacterium tuberculosis*, the Netherlands, 1993--2000

  Risk factor                    Beijing genotype   Total   (%)   Odds ratio   
  ------------------------------ ------------------ ------- ----- ------------ ---------------------
  **Y of diagnosis**                                                           
  1993                           23                 669     3     1.09         1.08 (1.03 to 1.13)
  1994                           41                 941     4     (per year)   
  1995                           56                 863     6                  
  1996                           50                 946     5                  
  1997                           64                 872     7                  
  1998                           58                 804     7                  
  1999                           74                 879     8                  
  2000                           49                 855     6                  
  **Sex**                                                                      
  Male                           254                4,135   6     1            
  Female                         161                2,694   6     0.97         
  **Age group**                                                                
  \<25                           120                1,522   8     1            1
  25--34                         123                1,925   6     0.80         0.69 (0.53 to 0.91)
  35--44                         64                 1,080   6     0.74         0.60 (0.43 to 0.83)
  45--54                         23                 614     4     0.45         0.36 (0.23 to 0.57)
  55--64                         24                 493     5     0.60         0.55 (0.35 to 0.88)
  65--74                         40                 517     8     0.98         0.78 (0.52 to 1.15)
  75+                            21                 678     3     0.37         0.30 (0.18 to 0.50)
  **Nationality**                                                              
  Netherlands                    160                2,825   6     1            1
  Europe (central and eastern)   20                 231     9     1.58         1.27 (0.77 to 2.09)
  Turkey                         3                  339     1     0.15         0.12 (0.04 to 0.38)
  Morocco                        19                 650     3     0.50         0.41 (0.25 to 0.68)
  Somalia                        21                 957     2     0.37         0.27 (0.17 to 0.44)
  Africa (other)                 28                 594     5     0.82         0.63 (0.41 to 0.96)
  Asia                           140                786     18    3.61         3.01 (2.32 to 3.91)
  Other                          19                 345     6     0.97         0.86 (0.53 to 1.42)
  Unknown                        5                  102     5     0.86         0.73 (0.29 to 1.84)
  **RFLP clustering^a^**                                                       
  No                             212                3,227   7     1            
  Yes, first case                57                 1,052   5     0.81         
  Yes, later case                146                2,550   6     0.86         
  **Localization**                                                             
  Pulmonary                      268                4,064   7     1            
  Extrapulmonary                 113                2,122   5     0.80         
  Pulmonary and extrapulmonary   34                 643     5     0.79         
  **Residing in Netherlands**                                                  
  \<6 months                     46                 641     7     1            
  6--11 mo                       12                 301     4     0.54         
  12--23 mo                      28                 358     8     1.10         
  2--4 y                         53                 767     7     0.96         
  [\>]{.ul}5 y                   122                1,710   7     0.99         
  Born in Netherlands            117                2,437   5     0.65         
  No information                 37                 615     6     0.83         
  **Drug resistance**                                                          
  Susceptible                    332                5,910   6     1            
  H only                         11                 227     5     0.86         
  S only                         34                 358     9     1.76         
  Other patterns                 26                 221     12    2.24         
  Multidrug-resistant            9                  53      17    3.44         
  Unknown                        3                  60      5     0.88         
  **Multidrug resistance**                                                     
  Yes                            9                  53      17    3.21         2.64 (1.22 to 5.74)
  No                             406                6,776   6     1            1
  **HIV infection**                                                            
  Yes                            14                 294     5     0.76         
  No                             401                6,535   6     1            

^a^RFLP, restriction fragment length polymorphism.

^b^Adjusted for year of diagnosis, age, nationality, and multidrug resistance

The association between the proportion of TB cases with the Beijing genotype and age was observed in particular in Dutch patients (chi square~trend~ 15.5; p\<0.0001), and was not clear among non-Dutch patients (chi square~trend~ 0.8; p\>0.2). Among Dutch patients, the Beijing genotype was more commonly found in new cases (6%, 133/2,130) than among retreated cases (4%, 18/498; p\<0.05). Among non-Dutch patients, the Beijing genotype was slightly more common in retreated cases (8%, 19/229) than in new cases (6%, 204/3,218); however, this occurrence was not significant (p\>0.2). The incidence pattern by person and time appears consistent with transmission of the Beijing genotype from immigrants to the Dutch population ([@R19]).

The proportion of TB cases with the Beijing genotype was not substantially associated with HIV infection, pulmonary localization, RFLP clustering, or duration of stay in the Netherlands ([Table](#T1){ref-type="table"}). The lack of association with RFLP-clustering suggests that the Beijing genotype is not spreading more quickly than other *M. tuberculosis* strains.

Of the nine patients with the Beijing genotype and multidrug resistance, four were from central and eastern Europe, three from Asia, one from Africa, and one from the Netherlands. One of these nine patients was RFLP-clustered; the other patient in that RFLP cluster had been diagnosed previously and had isolated isoniazid resistance.

During 1993 to 2000 in the Netherlands, the Beijing genotype represented 6% of TB cases. The Beijing genotype was associated with recent diagnoses, young age (in particular among Dutch citizens), nationality (Eastern Europe and Asia), and multidrug resistance. Although the Beijing genotype was associated with multidrug resistance, the number of MDRTB cases was small. No secondary cases were observed with the Beijing genotype and MDRTB. Of the nine cases of MDRTB, only one case may have been caused by transmission within the Netherlands from a case-patient who had isoniazid resistance at the start of treatment and may have acquired rifampicin resistance during treatment. However, the spread of the Beijing genotype among young people suggests the emergence of multidrug resistance and emphasizes the need for continued surveillance.
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